(SLGL) Sol-Gel Technologies Ltd. SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SLGL) Sol-Gel Technologies Ltd. Complete Analysis Pack
Go Beyond the Preview—Access the Full Reference Sources
This Sol-Gel Technologies Ltd. SWOT Analysis summarizes the company’s core products, applications, and strategic position—showing strengths, weaknesses, opportunities, and threats in a concise framework. The page includes a real preview/sample of the analysis so you can judge style and depth; purchase the full version to download the complete ready-to-use report for research, strategy, or investment work.
Strengths
2 Phase III assets: Twyneo and Epsolay
Sol-Gel has 2 late-stage dermatology assets, Twyneo for acne vulgaris and Epsolay for papulopustular rosacea, both backed by completed Phase III programs. That lowers development risk versus earlier pipeline drugs and gives the portfolio stronger clinical proof. Two Phase III wins also support faster commercial credibility and partner interest.
Microencapsulation technology platform
Sol-Gel’s microencapsulation platform is a real moat: it supports controlled drug release in topical skin care and helps the company differentiate against plain-gel competitors. The platform underpins its 2 FDA-approved dermatology products, Epsolay and Twyneo, and gives the pipeline a proprietary base that can support premium positioning. That matters because niche topical brands often win on formulation, not scale.
Commercial partnership with Perrigo
Sol-Gel's partnership with Perrigo strengthens commercialization by tapping Perrigo's established OTC reach and sales infrastructure. In 2025, Sol-Gel reported $11.5 million in revenue, showing how external partners can help a small biotech turn assets into sales while limiting operating burden. That setup can also speed market access and lower execution risk.
Broad dermatology pipeline: 6 named programs
Sol-Gel Technologies Ltd. has 6 named programs across acne, rosacea, palmoplantar keratoderma, psoriasis, and other skin diseases, led by Twyneo, Epsolay, SGT-210, erlotinib, tapinarof, and roflumilast. That breadth lowers single-asset risk and gives the Company more shots at commercial value. Twyneo and Epsolay are already approved, so the pipeline is not just early-stage optionality.
- 6 named programs
- Broad skin-disease coverage
- Multiple value catalysts
- Lower dependence on one asset
Established since 1997, Israel-based
Founded in 1997 and based in Ness Ziona, Israel, Sol-Gel Technologies Ltd. brings 29 years of operating history to its dermatology work. That long track record points to steady focus in skin-drug development, which matters in a field where clinical cycles can run for years.
- 1997 founding supports continuity
- Ness Ziona base anchors R&D in Israel
- Specialized dermatology focus aids expertise
- 29 years of operating history in 2026
A specialized Israeli scientific base can help keep research, talent, and product development tightly connected. For a small biopharma name, that kind of continuity is a real strength.
Sol-Gel’s FDA-Approved Portfolio and Pipeline Drive Growth
Sol-Gel Technologies Ltd.'s biggest strengths are its 2 FDA-approved dermatology products, Twyneo and Epsolay, plus a 6-program pipeline that cuts single-asset risk. Its microencapsulation platform helps the Company differentiate topical drugs and support controlled release. Perrigo's reach also helped Sol-Gel Technologies Ltd. generate $11.5 million in 2025 revenue.
| Strength | Data |
|---|---|
| Approved products | 2 |
| Named programs | 6 |
| 2025 revenue | $11.5M |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing Sol-Gel Technologies Ltd.’s business strategy
Editable Excel File
Provides a quick, structured Sol-Gel Technologies Ltd. SWOT snapshot to simplify strategic decisions.
Reference Sources
Lists primary, reputable sources (industry reports, gov data, benchmarks) to speed due diligence and let investors verify Sol-Gel Technologies’ market, pricing, and unit-economics claims.
Weaknesses
Clinical-stage revenue dependence
Sol-Gel Technologies Ltd. is still a clinical-stage Company, so revenue stays limited versus established drug makers. Its sales base depends on future approvals and product launches, not a broad commercial portfolio. That means cash generation is still uneven and tied to trial progress, regulatory wins, and launch timing.
No approved flagship products stated
Sol-Gel Technologies Ltd. has 2 approved products, Epsolay and Twyneo, but neither has become a flagship seller. That leaves cash generation tight versus R&D and launch costs. Without a bigger approved portfolio, Sol-Gel Technologies Ltd. stays reliant on fundraising, partnerships, and milestone income.
Single-therapeutic focus: dermatology
Sol-Gel Technologies is concentrated in skin-applied medicines, so it lacks diversification across disease areas. In its latest annual filing, it reported only $3.6 million of revenue and an accumulated deficit above $300 million, which shows how exposed the business is to dermatology demand and trial outcomes. If one program weakens, there is little else to offset the hit.
Geographic concentration in Israel
Sol-Gel Technologies Ltd. keeps most development and commercialization work in Israel, so a single-country base creates operational risk if local labor, logistics, or regulation get disrupted. It also limits scale versus global peers with larger U.S. or EU sales and manufacturing footprints. One location can be efficient, but it narrows reach.
- Most activity is centered in Israel.
- Single-site exposure raises disruption risk.
- Global peers often have wider infrastructure.
This concentration can slow partner access and commercial execution outside Israel, where larger biopharma hubs offer deeper capital, regulatory, and launch support.
Pipeline still carries development risk
Sol-Gel Technologies Ltd.'s pipeline still carries real development risk because SGT-210 is only in Phase I, while other assets remain investigational. In industry data, Phase I-to-approval success is only about 7.9%, so even promising early programs can fail before value shows up.
- SGT-210 is still early-stage.
- Other assets remain investigational.
- Phase I has the highest failure risk.
- Future value creation is still uncertain.
That keeps Sol-Gel Technologies Ltd.'s upside tied to trial readouts, not just product ideas. One weak data set can reset timelines, delay partnering, and pressure valuation fast.
Sol-Gel’s Scale Problem: Tiny Revenue, Huge Deficit
Sol-Gel Technologies Ltd. remains weak on scale: 2025 revenue was $3.6 million, while the accumulated deficit topped $300 million. With only 2 approved products, Epsolay and Twyneo, and SGT-210 still in Phase I, cash flow depends on approvals, launches, and funding.
| Weakness | 2025/2026 data |
|---|---|
| Revenue | $3.6 million |
| Accumulated deficit | Over $300 million |
Full Version Awaits
Sol-Gel Technologies Ltd. Reference Sources
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and once purchased you’ll receive the complete, editable version with in-depth strengths, weaknesses, opportunities, and threats tailored to Sol-Gel Technologies Ltd.
Opportunities
Launch potential from 2 completed Phase III assets
Twyneo and Epsolay give Sol-Gel Technologies Ltd. two Phase III assets that can move from R&D to sales if execution is clean. Both are once-daily dermatology products, and that dosing profile can help uptake when efficacy and skin tolerability are strong. With 2 launch candidates already de-risked by late-stage data, even modest commercial traction could turn them into real revenue drivers.
Expansion into psoriasis and related indications
Sol-Gel Technologies Ltd. is testing Erlotinib, Tapinarof, and Roflumilast for psoriasis and related skin diseases, which could open a much larger market than acne and rosacea. Psoriasis affects about 125 million people worldwide, and its chronic nature supports repeat treatment demand. If Sol-Gel Technologies Ltd. wins traction here, it could diversify revenue and reduce product-concentration risk.
Generic topical dermatology portfolio
Sol-Gel Technologies Ltd.’s generic topical dermatology portfolio can reach market faster than novel drugs because generic filings often use the ANDA path, which cuts development risk and time. That helps diversify revenue beyond a single innovation cycle and can support steadier sales if one launch slips. With U.S. topical dermatology spending still running in the billions, even one approved generic can matter.
Leverage of Perrigo commercialization scale
Perrigo’s scale can speed Sol-Gel Technologies Ltd.’s reach in topical consumer-health and dermatology, because a larger partner can fund launch execution, branding, and supply-chain rollout. Perrigo reported 2025 net sales of about $4.4 billion, giving it more room to push products into pharmacies and mass retail.
This matters for Sol-Gel Technologies Ltd. because faster distribution can shorten time to market and improve shelf presence without Sol-Gel Technologies Ltd. building the network alone. If Perrigo converts even a small share of its commercial base, the upside can be meaningful for niche dermatology launches.
- Faster distribution
- Stronger brand support
- Better supply-chain execution
- Higher retail penetration
Unmet need in once-daily non-antibiotic treatments
Twyneo fits an unmet need because it is a once-daily, non-antibiotic acne cream, and acne affects about 50 million people in the U.S. each year. That convenience can matter: simpler dosing and no antibiotic exposure may lift patient adherence and make dermatologists more open to use.
- Once-daily use can improve adherence.
- Non-antibiotic therapy fits stewardship trends.
- Clear use case may widen physician acceptance.
Sol-Gel’s Growth Hinges on Twyneo, Epsolay, and Fast-Track Pipeline Wins
Sol-Gel Technologies Ltd. can grow by converting Twyneo and Epsolay into revenue, while its psoriasis pipeline targets a market of about 125 million patients worldwide. Perrigo’s 2025 net sales of about $4.4 billion may also help push launches faster through retail and pharmacy channels. Generic topical filings add a quicker, lower-risk path to sales.
| Opportunity | Data |
|---|---|
| Psoriasis pipeline | 125M patients |
| Perrigo scale | $4.4B 2025 sales |
| Acne base | 50M U.S. yearly |
Threats
Regulatory and clinical trial failure risk
Sol-Gel Technologies Ltd. still faces a real approval cliff: any Phase I or other investigational setback can erase program value fast. With FDA timelines often slipping by months, even a short delay can push cash burn higher and force more dilution. For a small biotech, one failed trial can hit valuation harder than weak sales.
Intense dermatology competition
Sol-Gel Technologies Ltd. faces intense dermatology competition from large pharma firms and established skin-care specialists, many with stronger brands, payer coverage, and physician trust. That makes launch harder even after approval, because doctors often stay with familiar therapies. In a U.S. dermatology market worth tens of billions of dollars, gaining share usually needs clear efficacy, pricing, and access.
Pricing and reimbursement pressure
Sol-Gel Technologies Ltd.'s EPSOLAY and TWYNEO remain exposed to payer pressure because topical dermatology is often judged on cost per prescription, not just approval. In 2025, access and formulary tiering can still shape how fast pharmacies fill scripts and how much net revenue Sol-Gel keeps after rebates and discounts. If coverage is weak, uptake can stall even when the products are clinically approved.
Dependence on Perrigo and partners
Sol-Gel Technologies Ltd. depends on one major partner, Perrigo, for commercialization, so execution risk is concentrated in a single channel. If Perrigo shifts priorities, launches can slow and sales timing can slip. That also limits Sol-Gel Technologies Ltd.’s control over pricing, rollout pace, and market strategy.
- Single-partner dependence raises execution risk.
- Partner shifts can delay commercialization.
- Control over timing and strategy is limited.
Generic and substitutable product risk
Sol-Gel Technologies Ltd. faces high generic pricing pressure in topical drugs, where similar products can enter fast and push prices down. Even if volume rises, substitution and competition can squeeze gross margin and cut profit quality. This risk is sharper when payer and pharmacy buyers switch to the lowest-cost option.
- Fast generic entry erodes price
- Substitutes compress margins
- Volume growth may not lift profit
Sol-Gel’s Make-or-Break Risk: FDA Delays, Burn, and Perrigo Dependence
Sol-Gel Technologies Ltd. faces high binary risk: a Phase I or FDA delay can wipe out program value and raise 2025 cash burn. It also competes in a U.S. dermatology market worth tens of billions, where payer tiers and rebates can slow EPSOLAY and TWYNEO uptake. One Perrigo channel adds execution risk and limits control over launch timing.
| Threat | Latest data |
|---|---|
| Approval delay | Phase I setback; FDA slip = higher burn |
| Access pressure | 2025 formulary tiering affects net sales |
| Partner risk | 1 major partner: Perrigo |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.